CEL SCI CORP

Analysis for Ticker: CVM

Cel Sci Corporation operates as a biological host for clinical research that exists to convert shareholder money into administrative salaries and facility fees rather than commercial revenue. The company is currently in a state of financial collapse, admitting in its latest 05/2026 filings that it suffers from material weaknesses in its accounting and has substantial doubt it can survive for another year. They are currently attempting to extract 15,0$ million from the public through a new stock offering, but the math for any new investor is a disaster. If you buy a share at the target price of 3,07$, its actual tangible worth is only 1,91$, meaning 1,16$ of your money vanishes into the corporate deficit the moment you pay. This transaction will instantly dilute current owners by more than 50,0% while the company pays a 7,0% commission plus 185.000$ in fees to ThinkEquity LLC just to handle the sale. With cash reserves running dry and quarterly expenses exceeding 5,0$ million, they are desperate to fund a 30,0$ million to 35,0$ million study because their previous clinical efforts failed to get the drug approved for most patients. To see how they got here, you have to go back to 1983 when this financial machine first started. Over more than four decades, they have managed to lose exactly 544,8$ million without ever selling a product. In the 2024 fiscal year, they burned 27,6$ million. During that time, the corporate officers, including Geert Kersten, Patricia Prichep, and Eyal Talor, ensured their own checks would clear by securing employment agreements through 2027. In 05/2024, insiders acquired 58.000 shares for a mere 1,39$ each. By 10/2024, the company was already using its own stock as currency to pay bills, handing one million shares to a contractor called Ergomed Clinical Research Ltd to settle outstanding debts for services.